Publications by authors named "Marie-Pierre Fort"

Claim this Profile
R
Relevance of treatment-free remission recommendations in chronic phase chronic leukemia patients treated with frontline tyrosine kinase inhibitors.
Gabriel Etienne, Carole Faberes, Fréderic Bauduer, Didier Adiko, François Lifermann, Marie-Pierre Fort

Cancer Med· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidences of Deep Molecular Responses and Treatment-Free Remission in de Novo CP-CML Patients.
Gabriel Etienne, Stéphanie Dulucq, Fréderic Bauduer, Didier Adiko, François Lifermann, Marie-Pierre Fort

Cancers (Basel)· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
Gabriel Etienne, Stéphanie Dulucq, Carole Faberes, Fontanet Bijou, Anna Schmitt, Marie-Pierre Fort

Br J Haematol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors.
Gabriel Etienne, Stéphanie Dulucq, Françoise Huguet, Anna Schmitt, Axelle Lascaux, Marie-Pierre Fort

Cancer Med· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CML patients show sperm alterations at diagnosis that are not improved with imatinib treatment.
Franck-Emmanuel Nicolini, Vincent Alcazer, Françoise Huguet, Pascale Cony-Makhoul, Mael Heiblig, Marie-Pierre Fort

Leuk Res· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
Gabriel Etienne, Stéphanie Dulucq, Axelle Lascaux, Anna Schmitt, Audrey Bidet, Marie-Pierre Fort

Am J Hematol· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy.
Gabriel Etienne, Stéphanie Dulucq, Franck-Emmanuel Nicolini, Stéphane Morisset, Marie-Pierre Fort

Haematologica· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of the Y chromosome in Philadelphia-positive cells predicts a poor response of chronic myeloid leukemia patients to imatinib mesylate therapy.
Eric Lippert, Gabriel Etienne, Marie-Joelle Mozziconacci, Sophy Laibe, Carine Gervais, Marie-Pierre Fort

Haematologica· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
Marie Colombat, Marie-Pierre Fort, Claudine Chollet, Gerald Marit, Catherine Roche

Haematologica· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis